BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Pasari AS, Gupta S, Gurjar P, Ramteke V, Malde S, Pawar T, Jeyachandran V, Kashiv P, Dubey S, Kurundwadkar M, Sejpal K, Bawankule C, Deshpande N, Balwani MR. Efficacy of finerenone in reducing proteinuria in diabetic kidney disease with maximum tolerable doses of dapagliflozin and telmisartan. World J Nephrol 2026; 15(1): 117173 [PMID: 41884240 DOI: 10.5527/wjn.v15.i1.117173]
URL: https://www.wjgnet.com/2220-6124/full/v15/i1/117173.htm
Number Citing Articles
1
Vaia D Raikou, Sotiris Gavriil. Letter to the Editor: Finerenone and proteinuria in diabetic kidney diseaseWorld Journal of Nephrology 2026; 15(3): 121881 doi: 10.5527/wjn.121881
2
Sydney Mpisa, Jonathan Soldera. From kidney to liver: Are sodium–glucose cotransporter-2 inhibitors emerging as metabolic disease modifiers?World Journal of Nephrology 2026; 15(3): 121652 doi: 10.5527/wjn.121652
3
Antresa Jose, Abul Bashar Mohammad Kamrul-Hasan, Cornelius J Fernandez, Joseph M Pappachan. Efficacy of finerenone in reducing proteinuria in diabetic kidney disease on dapagliflozin and telmisartan: A disease-modifying approachWorld Journal of Nephrology 2026; 15(3): 120295 doi: 10.5527/wjn.120295